041 - 2015 Dietary Guidelines for Americans
In this episode, we discuss the 2015-2020 Dietary Guidelines for Americans published by the U.S. Department of Health and Human Services and U.S. Department of Agriculture.
Mar 29, 2016•34 min
HelixTalk - Rosalind Franklin University's College of Pharmacy Podcast
This podcast is produced by pharmacy faculty to supplement study material and provide relevant drug and professional topics. We're hoping that our real-life clinical pearls and discussions will help you stay up-to-date and improve your pharmacy knowledge.
Last refreshed: ⓘ
Follow this podcast in the Metacast mobile app to refresh it and see new episodes.
Podcasts are better in Metacast mobile app
Don't just listen to podcasts. Learn from them with transcripts, summaries, and chapters for every episode. Skim, search, and bookmark insights. Learn more
Episodes
040 - Homeopathic Medicine
In this episode, we discuss the many facets of homeopathic medications, including legal status in the United States, safety and efficacy data, and the ethics of homeopathy from the point of view of practicing pharmacists.
Mar 08, 2016•37 min
039 - Diclegis (doxylamine-pyridoxine) and nausea/vomiting of pregnancy
In this episode, we discuss nausea and vomiting of pregnancy (NVP) with a particular focus on Diclegis (doxylamine/pyridoxine).
Feb 16, 2016•28 min
038 - Suvarexant (Belsomra) - a new drug class for insomnia
In this episode, we discuss suvarexant (Belsomra), the first dual orexin receptor antagonist approved in the United States for the treatment of insomnia.
Jan 26, 2016•40 min
037 - Understanding Creatinine Clearance
In this episode, we have an in-depth review of how to measure glomerular filtration rate (GFR), including variants of the Cockcroft-Gault equation and newer, more accurate methods that may eventually be used to renally adjust certain medications.
Jan 05, 2016•29 min
036 - Two new agents for schizophrenia
In this episode, we discuss two agents newly approved for schizophrenia -- Rexulti (brexpiprazole) and cariprazine (Vraylar).
Dec 15, 2015•33 min
035 - Empagliflozin and dulaglutide
In this episode, we discuss two new anti-diabetic medications: empagliflozin (Jardiance) and the EMPA-REG OUTCOME trial as well as dulaglutide (Trulicity), a new GLP1 agonist.
Nov 24, 2015•34 min
034 - New Injectable Insulins
In this podcast, we discuss three new injectable insulin formations: Toujeo (insulin glargine U-300), Humalog U-200 (insulin lispro), and Tresiba (insulin degludec).
Nov 03, 2015•31 min
033 - PCSK9 Inhibitors
In this episode, we discuss PCSK9 inhibitors, a new drug class for LDL lowering, with a particular focus on alirocumab (Praluent).
Oct 13, 2015•32 min
032 - ARNIs and Entresto
In this episode, we discuss the new drug class, ARNI, recently approved for heart failure with a focus on sacubatril/valsartan (Entresto) and the PARADIGM-HF trial.
Sep 22, 2015•33 min
031 - Therapeutic Drug Monitoring III
In this episode, we discuss the therapeutic drug monitoring and dose adjustments for tacrolimus (Prograf) and lithium.
Sep 01, 2015•27 min
030 - Therapeutic Drug Monitoring II
In this episode, we discuss the therapeutic drug monitoring and dose adjustments for valproic acid (Depakote/Depakene/Depakon) and digoxin (Lanoxin).
Aug 11, 2015•42 min
029 - Therapeutic Drug Monitoring I
In this episode, we discuss the therapeutic drug monitoring and dose adjustments for warfarin (Coumadin) and phenytoin (Dilantin).
Jul 21, 2015•40 min
028 - Malaria Prophylaxis
In this episode, we discuss malaria prophylaxis with atovaquone/proguanil, chloroquine, hydroxychloroquine, doxycycline, mefloquine, and primaquine.
Jun 30, 2015•29 min
027 - Six Pivotal Drug Classes, Part 2
In this episode, we discuss six pivotal drug classes that have been FDA approved within the past 20 years. This is part 2 of a 2 part episode.
Jun 09, 2015•35 min
026 - Six Pivotal Drug Classes, Part 1
In this episode, we discuss six pivotal drug classes that have been FDA approved within the past 20 years. This is part 1 of a 2 part episode.
May 19, 2015•31 min
025 - An Interview with Dr. Brad Cannon, PharmD
In this episode, we interview Brad Cannon, PharmD regarding his career path in pharmacy and his viewpoints on the pharmacy profession.
Apr 28, 2015•34 min
024 - Case vignettes of depression, hypertension, and diabetes mellitus
In this episode, we discuss the optimal drug therapy for three different case vignettes -- depression, hypertension, and diabetes mellitus.
Apr 07, 2015•38 min
023 - Hepatitis C
In this episode, we review historical and new treatment options for hepatitis C, including: peginterferon, rivabirin, boceprevir, telaprevir, sofosbuvir (Sovaldi), simeprevir (Olysio), ombitasvir/paritaprevir/ritonavir/dasabuvir (Viekira Pak), and ledipasvir/sofosbuvir (Harvoni). May 18, 2015 - Correction added in the beginning of the episode regarding Viekira Pak dosing regimen.
Mar 16, 2015•38 min
022 - Sedation Minimization
In this episode, we discuss the pharmacology of oversedation, the importance of sedation minimization strategies in mechanically ventilated patients, and overview the sedatives and analgesics commonly used in this patient population.
Mar 03, 2015•28 min
021 - Opioid-Induced Respiratory Depression, Reversal, and Non-Narcotic Alternatives
In this episode, we discuss risk factors for opioid-related adverse events, naloxone (Narcan, Evzio), and a number of non-narcotic agents for neuropathic pain.
Feb 10, 2015•32 min
020 - SMART
In this episode, we summarize and discuss the clinical implications of the SMART trial (Salmeterol Multicenter Asthma Research Trial; Nelson et al, 2006).
Jan 20, 2015•22 min
019 - Immunizations
In this episode, we discuss two controversial topics in the world of immunizations with Dr. Angelo -- the "high-dose" influenza vaccine and the expanded use of PCV13 (Prevnar-13).
Dec 16, 2014•21 min
018 - HIV
In this episode, we review HIV therapy with Dr. Cottreau with a particular focus on Truvada, Atripla, Complera, Stribild, and Triumeq.
Dec 02, 2014•35 min
017 - Overactive bladder
In this episode, we discuss the management of overactive bladder, including: oxybutynin (Ditropan, Oxytrol), tolterodine (Detrol), trospium (Sanctura), solifenacin (VESIcare), darifenacin (Enablex), fesoterodine (Toviaz), mirabegron (Myrbetriq), and onabotulinumtoxinA (Botox).
Nov 18, 2014•23 min
016 - New diabetes medications
In this episode, we discuss newly approved agents for diabetes mellitus: Afrezza (inhaled human insulin), SGLT2 inhibitors (Invokana, Farxiga, Jardiance), and long-acting GLP-1 agonists (Bydureon, Tanzeum).
Nov 04, 2014•36 min
015 - Cancer Screenings
In this episode, we review a wide variety of cancer screening guidelines with a particular focus on the two most controversial screening areas: breast cancer screening with mammography and prostate cancer screening with PSA levels.
Oct 21, 2014•1 hr 2 min
014 - Midyear Table Talk
In this episode, we have a roundtable discussion regarding ASHP Midyear and the process of pursuing a pharmacy residency program.
Oct 07, 2014•31 min
013 - Obesity Guidelines and Weight Loss Pharmacotherapy
In this episode, we discuss the new 2013 ACC/AHA obesity guidelines with a particular focus on three medications for obesity: lorcaserin (Belviq), phentermine/topiramate (Qsymia), and orlistat (Xenical, Alli).
Sep 23, 2014•37 min
012 - Osteoporosis Guidelines and Two Newer Agents
In this episode, we review the National Osteoporosis Foundation's osteoporosis guidelines with a particular focus on two newer agents, denosumab (Prolia) and teriparatide (Forteo).
Sep 09, 2014•33 min
Hosted on Libsyn
For the best experience, listen in Metacast app for iOS or Android